MenB 220030

MenB 220030 Study

Help us move MenB prevention research forward

<span style="font-size:11.5pt;line-height:115%; font-family:"Arial Narrow",sans-serif;mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;mso-bidi-font-family:Shruti;mso-bidi-theme-font: minor-bidi;mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language: AR-SA">Help us move MenB prevention research forward </span></b></div>

Join a clinical study researching a meningitis booster vaccine in children and young adults

The MenB 220030 Study is looking at a vaccine that is already available in your country to help prevent meningitis in children and teenagers. This study wants to see:

how safe the vaccine (called the ‘study vaccine’) is and how well it works to help prevent meningitis in healthy children, teenagers, and young adults when given as a booster dose
if a booster dose of the study vaccine works better than the initial vaccinations alone.

We are looking for people to take part in this study who:

are 10–20 years of age and
have received the meningitis vaccine before

have never received the meningitis vaccine.

About the MenB 220030 Study

The study vaccine is recommended as part of immunisation plans to prevent meningitis B in children. The study will last for about 1 month, and participants will have 2 visits to the study centre. There will be no cost for the study vaccines, health assessments, and medical tests.

An Institutional Review Board (IRB)/Ethics Committee (EC) has reviewed this study. An IRB/EC protects the rights, safety, and well-being of study participants.